X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (98) 98
life sciences & biomedicine (90) 90
humans (82) 82
male (64) 64
chronic hepatitis c (63) 63
female (62) 62
hepatitis c virus (62) 62
middle aged (61) 61
hepatitis c, chronic - drug therapy (60) 60
hepatitis c (59) 59
ribavirin (57) 57
adult (52) 52
antiviral agents - therapeutic use (51) 51
treatment outcome (49) 49
drug therapy, combination (46) 46
gastroenterology & hepatology (46) 46
hepacivirus - genetics (46) 46
genotype (45) 45
ribavirin - therapeutic use (43) 43
aged (42) 42
interferon (36) 36
interferon-alpha - therapeutic use (36) 36
hepatitis (33) 33
hepatitis c, chronic - virology (33) 33
antiviral agents - administration & dosage (31) 31
infectious diseases (30) 30
biological response modifiers (29) 29
care and treatment (27) 27
polyethylene glycols - therapeutic use (26) 26
ribavirin - administration & dosage (24) 24
virology (24) 24
analysis (23) 23
recombinant proteins (22) 22
genetic aspects (21) 21
patients (21) 21
viral load (21) 21
virus diseases (21) 21
antiviral agents (20) 20
health aspects (20) 20
rna, viral - blood (20) 20
interferon-alpha - administration & dosage (19) 19
hepacivirus - drug effects (17) 17
hepacivirus - isolation & purification (17) 17
plus ribavirin (17) 17
polyethylene glycols - administration & dosage (17) 17
hepatology (16) 16
recombinant proteins - therapeutic use (16) 16
pegylated interferon plus ribavirin (15) 15
rna (15) 15
療法 (15) 15
gastroenterology (14) 14
genotypes (14) 14
hepacivirus - classification (14) 14
hepatitis c - drug therapy (14) 14
therapy (14) 14
慢性 (14) 14
drug therapy (13) 13
hepatitis c, chronic - blood (13) 13
interleukins - genetics (13) 13
medicine & public health (13) 13
sustained virologic response (13) 13
併用 (13) 13
慢性肝炎 (13) 13
肝炎 (13) 13
c型 (12) 12
c型慢性肝炎 (12) 12
young adult (12) 12
antiviral agents - adverse effects (11) 11
chronic infection (11) 11
hcv (11) 11
infections (11) 11
retrospective studies (11) 11
risk factors (11) 11
time factors (11) 11
併用療法 (11) 11
gastroenterology and hepatology (10) 10
hepatitis c, chronic - complications (10) 10
il28b (10) 10
liver (10) 10
peginterferon (10) 10
peginterferon alpha-2a (10) 10
recombinant proteins - administration & dosage (10) 10
sustained virological response (10) 10
chronic (9) 9
colorectal surgery (9) 9
ifn (9) 9
interferon alpha-2 (9) 9
internal medicine (9) 9
medical research (9) 9
sofosbuvir (9) 9
aged, 80 and over (8) 8
c (8) 8
cirrhosis (8) 8
efficacy (8) 8
general & internal medicine (8) 8
immunology (8) 8
infection (8) 8
medicine, experimental (8) 8
medicine, general & internal (8) 8
pegylated interferon plus ribavirin therapy (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 03/2015, Volume 385, Issue 9973, pp. 1075 - 1086
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 54, Issue 4, pp. 604 - 611
Journal Article
PloS one, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, pp. e67770 - e67770
...) on PEG-IFN/ribavirin (P/R) therapy have high chance of sustained virological response (SVR). To analyze host immunological factors associated with RVR, viral kinetics... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | T-Lymphocyte Subsets - immunology | Hepatitis C, Chronic - metabolism | Leukocytes, Mononuclear - metabolism | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Viral Load | Leukocytes, Mononuclear - immunology | Inflammation Mediators - metabolism | Adult | Female | Drug Therapy, Combination | Leukocytes, Mononuclear - drug effects | Cytokines - metabolism | Antiviral Agents - therapeutic use | Lymphocyte Activation | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Toll-Like Receptor 4 - metabolism | Phenotype | T-Lymphocyte Subsets - metabolism | Aged | Killer Cells, Natural - metabolism | Production management | Care and treatment | Interferon | B cells | Hepatitis C | Analysis | Therapy | Ionomycin | Laboratories | Liver | Leukocytes (mononuclear) | Infections | Lymphocytes T | Ribavirin | Interleukin 6 | Proteins | Hepatitis | Interleukin 4 | Immunology | Interleukin 2 | Lymphocytes | Polyethylene glycol | Hepatology | Gastroenterology | Toll-like receptors | Peripheral blood mononuclear cells | Immune system | Cytokines | Blood & organ donations | 12-O-Tetradecanoylphorbol-13-acetate | Inflammation | TLR4 protein | Tumor necrosis factor-α | Gene expression | Patients | Medicine | Monocytes | γ-Interferon | Interleukin 10 | Kinetics | Hepatitis C virus | Acetic acid | Viral infections | Index Medicus
Journal Article
Journal of microbiology, immunology and infection, ISSN 1684-1182, 08/2019, Volume 52, Issue 4, pp. 556 - 562
.... Peginterferon and ribavirin (PegIFN/RBV) have been the standard-of-care for chronic hepatitis C virus (HCV... 
Prison | Pegylated interferon plus ribavirin | Chronic hepatitis C | Direct-acting antiviral agents (DAAs) | Cost-effectiveness | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology
Journal Article
Journal of gastroenterology, ISSN 0944-1174, 3/2016, Volume 51, Issue 3, pp. 252 - 259
Hyperbilirubinemia, mild or moderate, is a commonly observed laboratory abnormality in chronic hepatitis C patients treated with simeprevir with pegylated interferon (Peg-IFN) plus ribavirin... 
Pegylated interferon plus ribavirin | Simeprevir | Chronic hepatitis C | Medicine & Public Health | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Inosine triphosphate pyrophosphatase | Surgical Oncology | Bilirubin increase | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Prospective Studies | Humans | Middle Aged | Pyrophosphatases - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Simeprevir - therapeutic use | Simeprevir - adverse effects | Hyperbilirubinemia - chemically induced | Female | Drug Therapy, Combination | Hyperbilirubinemia - genetics | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Risk Factors | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Bilirubin - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Hyperbilirubinemia - blood | Interferon alpha-2 | Aged | Interferon-alpha - adverse effects | Care and treatment | Analysis | Hemoglobin | Interferon | Genetic aspects | Bilirubin | Biological response modifiers | Hepatitis C | Ribavirin | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 01/2018, Volume 115, Issue 2, pp. E162 - E171
Journal Article
BMC infectious diseases, ISSN 1471-2334, 05/2011, Volume 11, Issue 1, pp. 124 - 124
Journal Article
Journal Article